Core Viewpoint - The stock of Baiaosaitu-B (02135) has seen a significant increase of over 7% in the afternoon trading session, attributed to recent licensing agreements with Tubulis and Merck, highlighting the company's competitive edge in the antibody development sector [1] Group 1: Licensing Agreements - On September 16, Baiaosaitu announced a licensing agreement with German ADC developer Tubulis, utilizing its proprietary RenMice fully human antibody development platform for innovative ADC therapies [1] - Under the agreement with Tubulis, Baiaosaitu will receive an upfront payment, milestone payments related to development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - Earlier, on September 4, Baiaosaitu signed an antibody option and evaluation agreement with Merck, focusing on evaluating antibodies developed from the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Performance - As of the report, Baiaosaitu's stock price is at 26.58 HKD, with a trading volume of 16.7354 million HKD, reflecting a 4.07% increase at the time of publication [1] - The recent agreements with Tubulis and Merck underscore the international competitiveness and drug conversion potential of Baiaosaitu's fully human antibody platform, as stated by the company's Chairman and CEO, Shen Yulei [1]
港股异动 午后涨超7% 再与Tubulis达成许可交易 公司月初与默克达成合作